Israel Englander Heron Therapeutics, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,434,627 shares of HRTX stock, worth $2.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,434,627

Previous 3,167,286 54.7%

Holding current value

$2.96 Million

Previous $8.77 Million 42.77%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.32 - $3.86 $4.02 Million - $6.69 Million	-1,732,659 Reduced 54.7%	1,434,627 $5.02 Million
Q1 2024 May 15, 2024	BUY	$1.71 - $3.06 $3.3 Million - $5.91 Million	1,930,129 Added 156.01%	3,167,286 $8.77 Million
Q4 2023 Feb 14, 2024	BUY	$0.54 - $1.82 $617,416 - $2.08 Million	1,143,363 Added 1219.02%	1,237,157 $2.1 Million
Q2 2023 Aug 14, 2023	SELL	$1.11 - $2.88 $523,913 - $1.36 Million	-471,994 Reduced 83.42%	93,794 $108,000
Q1 2023 May 15, 2023	SELL	$1.51 - $3.25 $4.44 Million - $9.56 Million	-2,940,566 Reduced 83.86%	565,788 $854,000
Q4 2022 Feb 14, 2023	BUY	$2.25 - $4.67 $4.11 Million - $8.52 Million	1,825,388 Added 108.59%	3,506,354 $8.77 Million
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $3.86 Million - $7.78 Million	1,449,328 Added 625.69%	1,680,966 $7.09 Million
Q2 2022 Aug 15, 2022	SELL	$2.3 - $6.29 $2.23 Million - $6.11 Million	-971,100 Reduced 80.74%	231,638 $646,000
Q1 2022 May 16, 2022	BUY	$4.63 - $9.94 $916,462 - $1.97 Million	197,940 Added 19.7%	1,202,738 $6.88 Million
Q4 2021 Feb 14, 2022	BUY	$8.35 - $12.6 $8.39 Million - $12.7 Million	1,004,798 New	1,004,798 $9.17 Million
Q3 2021 Nov 15, 2021	SELL	$10.13 - $15.0 $3.32 Million - $4.92 Million	-327,721 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.27 - $18.48 $9.45 Million - $13.2 Million	-712,125 Reduced 68.48%	327,721 $5.09 Million
Q1 2021 May 17, 2021	BUY	$14.49 - $20.72 $12.2 Million - $17.4 Million	839,815 Added 419.84%	1,039,846 $16.9 Million
Q4 2020 Feb 16, 2021	SELL	$14.61 - $22.14 $61,464 - $93,142	-4,207 Reduced 2.06%	200,031 $4.23 Million
Q3 2020 Nov 16, 2020	BUY	$13.67 - $17.77 $2.79 Million - $3.63 Million	204,238 New	204,238 $3.03 Million
Q2 2020 Aug 14, 2020	SELL	$10.89 - $21.47 $5.53 Million - $10.9 Million	-507,854 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$10.23 - $24.56 $2.04 Million - $4.9 Million	-199,690 Reduced 28.22%	507,854 $5.96 Million
Q4 2019 Feb 14, 2020	BUY	$17.42 - $26.61 $2.45 Million - $3.74 Million	140,613 Added 24.8%	707,544 $16.6 Million
Q3 2019 Nov 14, 2019	BUY	$16.36 - $21.39 $3.56 Million - $4.65 Million	217,302 Added 62.15%	566,931 $10.5 Million
Q2 2019 Aug 15, 2019	BUY	$16.93 - $26.22 $5.71 Million - $8.84 Million	337,296 Added 2734.91%	349,629 $6.5 Million
Q2 2019 Aug 14, 2019	SELL	$16.93 - $26.22 $885,726 - $1.37 Million	-52,317 Reduced 80.92%	12,333 $2.69 Million
Q1 2019 May 14, 2019	BUY	$23.15 - $28.34 $1.5 Million - $1.83 Million	64,650 New	64,650 $1.58 Million
Q4 2018 Feb 14, 2019	SELL	$22.03 - $32.01 $915,016 - $1.33 Million	-41,535 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$30.0 - $40.85 $4.13 Million - $5.63 Million	-137,829 Reduced 76.84%	41,535 $1.32 Million
Q2 2018 Aug 14, 2018	BUY	$26.4 - $42.0 $4.74 Million - $7.53 Million	179,364 New	179,364 $6.97 Million
Q1 2018 May 15, 2018	SELL	$18.43 - $28.8 $5.81 Million - $9.08 Million	-315,173 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$14.8 - $18.85 $809,574 - $1.03 Million	-54,701 Reduced 14.79%	315,173 $5.71 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $5.42 Million - $6.23 Million	369,874	369,874 $5.97 Million

Others Institutions Holding HRTX

# of Institutions

198

Shares Held

129M

Call Options Held

94.7K

Put Options Held

148K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $245M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account